Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis
| Autor: | Nancy Zhu, April Shamy, Ambica Parmar, Heather A. Leitch, Richard A. Wells, Michelle Geddes, Andrea Kew, Robert Delage, Alexandre Mamedov, Eve St. Hilaire, Martha Lenis, Janika Francis, Rajat Kumar, Lisa Chodirker, Mohamed Elemary, Rena Buckstein, Mary-Margaret Keating, Thomas J. Nevill, Brian Leber, Mitchell Sabloff, Karen W.L. Yee, Jessica Ivo, John M. Storring, Liying Zhang |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Risk Canada medicine.medical_specialty Pediatrics Iron Overload Multivariate analysis Comorbidity Iron Chelating Agents 03 medical and health sciences 0302 clinical medicine Cause of Death Internal medicine parasitic diseases medicine Overall survival Humans Transplantation Homologous Registries Aged Aged 80 and over Related factors business.industry Myelodysplastic syndromes Hazard ratio Hematopoietic Stem Cell Transplantation Hematology Iron chelation therapy Middle Aged Prognosis medicine.disease Survival Analysis Chelation Therapy 3. Good health International Prognostic Scoring System Myelodysplastic Syndromes 030220 oncology & carcinogenesis Female Erythrocyte Transfusion business 030215 immunology |
| Zdroj: | British Journal of Haematology. 179:83-97 |
| ISSN: | 0007-1048 |
| DOI: | 10.1111/bjh.14825 |
| Popis: | Summary Analyses suggest iron overload in red blood cell (RBC) transfusion-dependent (TD) patients with myleodysplastic syndrome (MDS) portends inferior overall survival (OS) that is attenuated by iron chelation therapy (ICT) but may be biassed by unbalanced patient-related factors. The Canadian MDS Registry prospectively measures frailty, comorbidity and disability. We analysed OS by receipt of ICT, adjusting for these patient-related factors. TD International Prognostic Scoring System (IPSS) low and intermediate-1 risk MDS, at RBC TD, were included. Predictive factors for OS were determined. A matched pair analysis considering age, revised IPSS, TD severity, time from MDS diagnosis to TD, and receipt of disease-modifying agents was conducted. Of 239 patients, 83 received ICT; frailty, comorbidity and disability did not differ from non-ICT patients. Median OS from TD was superior in ICT patients (5·2 vs. 2·1 years; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text